PMID- 34012627 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220423 IS - 2078-6891 (Print) IS - 2219-679X (Electronic) IS - 2078-6891 (Linking) VI - 12 IP - 2 DP - 2021 Apr TI - The efficacy and toxicity of adjuvant S-1 schedule with 2-week administration followed by 1-week rest in gastric cancer patients. PG - 297-306 LID - 10.21037/jgo-20-477 [doi] AB - BACKGROUND: This study aimed to investigate the clinical outcome of adjuvant S-1 with 2-week administration followed by a 1-week rest for locally advanced gastric cancer (GC) patients. METHODS: The current study was a single retrospective cohort study that focused on the efficacy and toxicity of adjuvant S-1 with a 3-week schedule. A total of 60 patients who underwent total or subtotal gastrectomy plus D2 lymph node dissection and adjuvant S-1 treatment were identified. S-1 treatment began within 4 weeks after the operation; it was administered orally for 2 weeks, followed by a 1-week rest. The dose of S-1 was adjusted depending on adverse events (AEs), with at least 80 mg administered daily. The completion of 1-year S-1 was defined as S-1 continuation for 1 year with over 70% of the planned dose. Patients were followed up with for 5 years postoperatively and underwent hematologic tests and assessments of clinical symptoms every 3-6 weeks for 1 year after surgery. Computed tomography of the abdomen and panendoscopy were performed every 6 months during the first 2 years and at 1-year intervals thereafter until year 5 after surgery. RESULTS: The completion rate of 1-year adjuvant S-1 was 71.7%, and the 3-year disease-free survival and overall survival rates were 70.2% and 79.5%, respectively. Seventeen patients did not complete S-1 for 1 year, including 11 patients with tumor recurrence and 6 patients who developed intolerance. Most AEs of S-1 were grade 1-2, and the most frequent AEs (>20%) included anemia, fatigue, pigmentation, nausea, and diarrhea. The most common grade 3-4 AE was fatigue, which was observed in 6.7% of patients. Most patients tolerated the side effects. CONCLUSIONS: The results of our study confirm that the efficacy and safety of schedule modification of adjuvant S-1 treatment in patients with GC who underwent gastrectomy with D2 lymph node dissection are equal to those in a previous phase 3 study. CI - 2021 Journal of Gastrointestinal Oncology. All rights reserved. FAU - Liu, Yu-Yin AU - Liu YY AD - Division of General Surgery, Department of Surgery, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung. FAU - Liu, Yueh-Wei AU - Liu YW AD - Division of General Surgery, Department of Surgery, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung. FAU - Chen, Yen-Yang AU - Chen YY AD - Department of Hematology-Oncology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung. FAU - Wang, Shih-Ho AU - Wang SH AD - Division of General Surgery, Department of Surgery, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung. FAU - Chuah, Seng-Kee AU - Chuah SK AD - Division of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung. FAU - Huang, Gong-Kai AU - Huang GK AD - Department of Anatomic Pathology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung. FAU - Chen, Yen-Hao AU - Chen YH AD - Department of Hematology-Oncology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung. AD - School of Medicine, Chung Shan Medical University, Taichung. AD - Department of Nursing, Meiho University, Pingtung. LA - eng PT - Journal Article PL - China TA - J Gastrointest Oncol JT - Journal of gastrointestinal oncology JID - 101557751 PMC - PMC8107597 OTO - NOTNLM OT - S-1 OT - adjuvant OT - gastrectomy OT - gastric cancer (GC) COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/jgo-20-477). The authors have no conflicts of interest to declare. EDAT- 2021/05/21 06:00 MHDA- 2021/05/21 06:01 PMCR- 2021/04/01 CRDT- 2021/05/20 06:43 PHST- 2021/05/20 06:43 [entrez] PHST- 2021/05/21 06:00 [pubmed] PHST- 2021/05/21 06:01 [medline] PHST- 2021/04/01 00:00 [pmc-release] AID - jgo-12-02-297 [pii] AID - 10.21037/jgo-20-477 [doi] PST - ppublish SO - J Gastrointest Oncol. 2021 Apr;12(2):297-306. doi: 10.21037/jgo-20-477.